Trial Profile
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Expanded access
- 14 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2012 Additional lead trial investigator (Seema Singhal) identified as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University.